Launch of Lysoveta, LPC-EPA/DHA from krill (first of its kind)
6 years of science, regulatory approval expected by end-2022
Unlocking new opportunities and opens new large markets
We view the announcement as highly supportive
24 Nov 2020
Launch of Lysoveta represents new growth leg
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Launch of Lysoveta represents new growth leg
Aker BioMarine ASA (AKBM:OSL) | 0 0 0.0%
- Published:
24 Nov 2020 -
Author:
Thomas Lorck | Axel Jacobsen -
Pages:
5
Launch of Lysoveta, LPC-EPA/DHA from krill (first of its kind)
6 years of science, regulatory approval expected by end-2022
Unlocking new opportunities and opens new large markets
We view the announcement as highly supportive